

## FedEx expands its strengthens Life Sciences Center in Korea to expand healthcare capabilities in APAC

12 November 2024 | News

**Advanced Korea Good Supply Practice (KGSP)-certified facility enables specialized temperature controlled solutions for the growing life science sector**



Federal Express Corporation (FedEx), one of the world's largest express transportation companies, has expanded its state-of-the-art Life Science Center in Gimpo, Gyeonggi-do, Korea.

This strategic enhancement, along with FedEx Life Science Centers in Singapore and Japan, is addressing the rising demand for a robust logistics network with advanced capabilities to support the rapidly growing healthcare industry across the Asia Pacific region. The advanced FedEx Korea Life Science Center spans 2,288 square meters – almost triple the size of the previous facility.

The new operation includes five temperature-controlled areas for temperatures ranging from  $-150^{\circ}\text{C}$  to  $+25^{\circ}\text{C}$ , which are monitored 24/7 to ensure continuous compliance with pharmaceutical cold chain requirements. The facility is also Korea Good Supply Practice (KGSP)- certified, in accordance with market-specific quality and regulatory requirements for the healthcare industry.

Along with temperature-controlled Inventory management capabilities, the Korea Life Science Center is equipped to support both domestic and international transportation needs. By expanding its capacity, FedEx is strengthening its life sciences logistics expertise, ensuring seamless and reliable transportation of critical healthcare shipments including investigational medicinal products (IMP), biological samples, and biopharmaceutical product lines while enabling pharmaceutical and clinical trials customers to prioritize patient care.

By expanding its capacity, FedEx is strengthening its life sciences logistics expertise, ensuring seamless and reliable transportation of critical healthcare shipments including investigational medicinal products (IMP), biological samples, and biopharmaceutical product lines while enabling pharmaceutical and clinical trials customers to prioritize patient care.